EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 16, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 18, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 04, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
October 31, 2024 16:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 28, 2024 17:14 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
October 28, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement...
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
October 24, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 16, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 16, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
September 04, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...